Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer

Cancer Immunology, Immunotherapy

Volumn 59, Issue 9, 2010, Pages 1389-1400

  Heller, A ^a   Zornig I ^a   Muller T ^a   Giorgadze, K ^a   Frei, C ^a   Giese, T ^a   Bergmann, F ^a   Schmidt, J ^a   Werner, J ^a   Buchler, M W ^a   Jaeger, D ^a   Giese, N A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Antibody; Immunoediting; MIA; Pancreatic cancer; PNLIPRP2; SEREX

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 3; MELANOMA INHIBITORY ACTIVITY PROTEIN; PANCREATIC LIPASE RELATED PROTEIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BYSTANDER EFFECT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGICAL ANALYSIS OF RECOMBINANT CDNA EXPRESSION LIBRARIES; SURVIVAL TIME;

ADENOCARCINOMA; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AUTOANTIBODIES; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LIBRARY; HUMANS; IMMUNOCHEMISTRY; LIPASE; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 77955510947     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0870-9     Document Type: Article

References (72)

1. A Jemal, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 4 225 249 10.3322/caac.20006 19474385
2. HH Wong NR Lemoine 2008 Biological approaches to therapy of pancreatic cancer Pancreatology 8 4-5 431 461 10.1159/000151536 18724071
3. FH Schmitz-Winnenthal, et al. 2005 High frequencies of functional tumor-reactive T-cells in bone marrow and blood of pancreatic cancer patients Cancer Res 65 21 10079 10087 10.1158/0008-5472.CAN-05-1098 16267034 1:CAS:528:DC%2BD2MXhtFKkt7rI (Pubitemid 41541490)
4. TH Patwa, et al. 2009 The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray Electrophoresis 30 12 2215 2226 10.1002/elps.200800857 19582723 1:CAS:528:DC%2BD1MXosVWks7w%3D
5. Hong SH et al (2006) Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer. Biomark Insights 1:175-183
6. B Tomaino, et al. 2007 Autoantibody signature in human ductal pancreatic adenocarcinoma J Proteome Res 6 10 4025 4031 10.1021/pr070281a 17824682 1:CAS:528:DC%2BD2sXhtVSgs7jM (Pubitemid 350032566)
7. B Kubuschok, et al. 2006 Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer Clin Cancer Res 12 4 1365 1372 10.1158/1078-0432.CCR-05-1672 16489095 1:CAS:528:DC%2BD28XhsFaluro%3D (Pubitemid 43342530)
8. M Ho, et al. 2005 Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients Clin Cancer Res 11 10 3814 3820 10.1158/1078-0432. CCR-04-2304 15897581 1:CAS:528:DC%2BD2MXktFyrurc%3D (Pubitemid 40685601)
9. JF Tseng, et al. 2005 Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations Pancreatology 5 1 67 74 10.1159/000084492 15775701 1:CAS:528: DC%2BD2MXjsFyrt7k%3D (Pubitemid 40674593)
10. SH Hong 2005 Identification of clp36 as a tumor antigen that induces an antibody response in pancreatic cancer Cancer Res Treat 37 1 71 77 10.4143/crt.2005.37.1.71 19956513
11. SH Hong, et al. 2004 An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer Cancer Res 64 15 5504 5510 10.1158/0008-5472.CAN-04-0077 15289361 1:CAS:528:DC%2BD2cXmtF2lsrk%3D (Pubitemid 39006575)
12. FM Johnston, et al. 2009 Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer Clin Cancer Res 15 21 6511 6518 10.1158/1078-0432.CCR-09-0565 19843662 1:CAS:528:DC%2BD1MXhtlCjsrnJ
13. D Laheru EM Jaffee 2005 Immunotherapy for pancreatic cancer - science driving clinical progress Nat Rev Cancer 5 6 459 467 10.1038/nrc1630 15905855 1:CAS:528:DC%2BD2MXks1Gmsrs%3D (Pubitemid 40791488)
14. D Laheru, et al. 2008 Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clin Cancer Res 14 5 1455 1463 10.1158/1078-0432.CCR-07-0371 18316569 1:CAS:528:DC%2BD1cXislSrsLk%3D (Pubitemid 351413929)
15. AJ Lepisto, et al. 2008 A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors Cancer Ther 6 B 955 964 19129927 1:CAS:528:DC%2BD1MXmsFSmtrg%3D
16. RK Ramanathan, et al. 2005 Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer Cancer Immunol Immunother 54 3 254 264 10.1007/s00262-004-0581-1 15372205 1:CAS:528:DC%2BD2MXjs1ahuw%3D%3D (Pubitemid 40174243)
17. K Yamamoto, et al. 2005 Muc1 peptide vaccination in patients with advanced pancreas or biliary tract cancer Anticancer Res 25 5 3575 3579 16101182 1:CAS:528:DC%2BD2MXps1Kgur0%3D
18. JA Kyte 2009 Cancer vaccination with telomerase peptide gv1001 Expert Opin Investig Drugs 18 5 687 694 10.1517/13543780902897631 19388882 1:CAS:528:DC%2BD1MXkvFChurc%3D
19. A Anichini, et al. 2004 The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma Cancer Immunol Immunother 53 10 855 864 10.1007/s00262-004-0526-8 15175905 (Pubitemid 39312653)
20. OJ Finn 2008 Cancer immunology N Engl J Med 358 25 2704 2715 10.1056/NEJMra072739 18565863 1:CAS:528:DC%2BD1cXns1ajt7k%3D (Pubitemid 351860863)
21. JA Kyte, et al. 2009 Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination Cancer Immunol Immunother 58 10 1609 1626 10.1007/s00262-009-0670-2 19221745 1:CAS:528:DC%2BD1MXptVent7k%3D
22. CM Koebel, et al. 2007 Adaptive immunity maintains occult cancer in an equilibrium state Nature 450 7171 903 907 10.1038/nature06309 18026089 1:CAS:528:DC%2BD2sXhtl2gsbjL (Pubitemid 350231320)
23. MW Teng, et al. 2008 Immune-mediated dormancy: an equilibrium with cancer J Leukoc Biol 84 4 988 993 10.1189/jlb.1107774 18515327 1:CAS:528: DC%2BD1cXht1amsbvJ
24. GP Dunn, et al. 2004 The three Es of cancer immunoediting Annu Rev Immunol 22 329 360 10.1146/annurev.immunol.22.012703.104803 15032581 1:CAS:528:DC%2BD2cXktlOgs7k%3D (Pubitemid 38680426)
25. M Reuschenbach, et al. 2009 A systematic review of humoral immune responses against tumor antigens Cancer Immunol Immunother 58 10 1535 1544 10.1007/s00262-009-0733-4 19562338 1:CAS:528:DC%2BD1MXptVentr4%3D
26. R Saffroy, et al. 1999 Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma Br J Cancer 79 3-4 604 610 10.1038/sj.bjc.6690095 10027337 1:STN:280:DyaK1M7kvFGrsQ%3D%3D (Pubitemid 29046243)
27. S Gansauge, et al. 1996 The role of anti-p53-autoantibodies in pancreatic disorders Int J Pancreatol 19 3 171 178 8807362 1:STN:280:DyaK28vgtV2rtA%3D%3D
28. E Jager, et al. 1998 Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes J Exp Med 187 2 265 270 10.1084/jem.187.2.265 9432985 1:CAS:528:DyaK1cXkvVyqug%3D%3D (Pubitemid 28060443)
29. M Muller, et al. 2006 Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers Int J Oncol 29 4 973 980 16964393
30. U Sahin, et al. 1995 Human neoplasms elicit multiple specific immune responses in the autologous host Proc Natl Acad Sci USA 92 25 11810 11813 10.1073/pnas.92.25.11810 8524854 1:CAS:528:DyaK2MXpvVOnt7w%3D (Pubitemid 26014201)
31. O Tureci, et al. 2005 Identification of tumor-associated autoantigens with SEREX Methods Mol Med 109 137 154 15585919
32. D Jager, et al. 2004 Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning Cancer Immunol Immunother 53 3 144 147 10.1007/s00262-003-0470-z 14727084 1:CAS:528: DC%2BD2cXhtlehsbo%3D (Pubitemid 38328035)
33. MJ Scanlan, et al. 2001 Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression Cancer Immunol 1 4 1:STN:280:DC%2BD3s3is1ClsA%3D%3D
34. T Nakatsura, et al. 2001 Gene cloning of immunogenic antigens overexpressed in pancreatic cancer Biochem Biophys Res Commun 281 4 936 944 10.1006/bbrc.2001.4377 11237751 1:CAS:528:DC%2BD3MXhs1Chtbg%3D (Pubitemid 32917821)
35. T Okada, et al. 2006 A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers Clin Cancer Res 12 1 191 197 10.1158/1078-0432.CCR-05-1206 16397042 1:CAS:528:DC%2BD28Xht1GltA%3D%3D (Pubitemid 43166194)
36. T Okada, et al. 2005 Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis Int J Cancer 116 6 925 933 10.1002/ijc.21118 15856462 1:CAS:528:DC%2BD2MXpsVegtLo%3D (Pubitemid 41209200)
37. K Antwi, et al. 2009 Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines Mol Immunol 46 15 2931 2937 10.1016/j.molimm.2009.06.021 19615748 1:CAS:528:DC%2BD1MXhtVaqsrzJ
38. K Antwi, et al. 2009 Analysis of the plasma peptidome from pancreas cancer patients connects a peptide in plasma to overexpression of the parent protein in tumors J Proteome Res 8 10 4722 4731 10.1021/pr900414f 19795908 1:CAS:528:DC%2BD1MXhtV2murjI
39. B Kubuschok, et al. 2004 Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis Int J Cancer 109 4 568 575 10.1002/ijc.20006 14991579 1:CAS:528:DC%2BD2cXislCisrc%3D (Pubitemid 38339648)
40. A Wadle, et al. 2006 Serological immune response to cancer testis antigens in patients with pancreatic cancer Int J Cancer 119 1 117 125 10.1002/ijc.21744 16432832 1:CAS:528:DC%2BD28XkslyjtL4%3D
41. S Gnjatic, et al. 2010 Seromic profiling of ovarian and pancreatic cancer Proc Natl Acad Sci USA 107 11 5088 5093 10.1073/pnas.0914213107 20194765
42. F Zhao, et al. 2009 Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma Immunology 128 1 134 140 10.1111/j.1365-2567.2009.03090.x 19689742 1:CAS:528:DC%2BD1MXhtVChtLnO
43. D Jager, et al. 2001 Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library Cancer Res 61 5 2055 2061 11280766 1:CAS:528:DC%2BD3MXit1OgsL8%3D
44. E Jager, et al. 2000 Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB40101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma J Exp Med 191 4 625 630 10.1084/jem.191.4.625 10684854 1:CAS:528:DC%2BD3cXhsVKqs7c%3D
45. E Stockert, et al. 1998 A survey of the humoral immune response of cancer patients to a panel of human tumor antigens J Exp Med 187 8 1349 1354 10.1084/jem.187.8.1349 9547346 1:CAS:528:DyaK1cXis1CqsrY%3D (Pubitemid 28189124)
46. P Sehr, et al. 2001 A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology J Immunol Methods 253 1-2 153 162 10.1016/S0022-1759(01)00376-3 11384677 1:CAS:528:DC%2BD3MXjvV2rsrs%3D (Pubitemid 32522523)
47. M Bartel, et al. 2008 Abnormal crosstalk between pancreatic acini and macrophages during the clearance of apoptotic cells in chronic pancreatitis J Pathol 215 2 195 203 10.1002/path.2348 18421760 1:CAS:528:DC%2BD1cXotFalurY%3D (Pubitemid 351786038)
48. GO Ceyhan, et al. 2009 Pancreatic neuropathy and neuropathic pain-a comprehensive pathomorphological study of 546 cases Gastroenterology 136 1 177 186 10.1053/j.gastro.2008.09.029 18992743 e171
49. J Koninger, et al. 2004 Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action Clin Cancer Res 10 14 4776 4783 10.1158/1078-0432.CCR-1190-03 15269152 (Pubitemid 38955530)
50. M Erkan, et al. 2007 Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity Gastroenterology 132 4 1447 1464 10.1053/j.gastro.2007.01.031 17408641 1:CAS:528:DC%2BD2sXlslKru7o%3D (Pubitemid 46627568)
51. S Shukla, et al. 2009 Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response Cancer Biomark 5 3 127 135 19407367 1:CAS:528:DC%2BD1MXmvVyjtbs%3D
52. FM Brichory, et al. 2001 An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer Proc Natl Acad Sci USA 98 17 9824 9829 10.1073/pnas. 171320598 11504947 1:CAS:528:DC%2BD3MXmtlCmsLw%3D (Pubitemid 32769388)
53. H Nakamura, et al. 2002 Antibodies against hepatoma-derived growth factor and mucosal repair in ulcerative colitis J Gastroenterol 37 Suppl 14 8 14 12572860 1:CAS:528:DC%2BD38Xpsleqt7s%3D
54. X Zhong, et al. 2004 Construction of human liver cancer vascular endothelium cDNA expression library and screening of the endothelium-associated antigen genes World J Gastroenterol 10 10 1402 1408 15133843 1:CAS:528:DC%2BD2cXns1Sju7s%3D
55. CJ Mooney, et al. 2006 Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis Int J Urol 13 3 211 217 10.1111/j.1442-2042.2006.01263.x 16643611 1:CAS:528:DC%2BD28XkvFOnsr0%3D
56. YY Shi, et al. 2005 Identification and analysis of tumour-associated antigens in hepatocellular carcinoma Br J Cancer 92 5 929 934 10.1038/sj.bjc.6602460 15756260 1:CAS:528:DC%2BD2MXitV2ju78%3D (Pubitemid 40462641)
57. Y Tanaka, et al. 2006 Proteomic surveillance of autoantigens in relapsing polychondritis Microbiol Immunol 50 2 117 126 16490929 1:CAS:528: DC%2BD28Xjt1GrsLg%3D
58. S Avrameas, et al. 1981 Natural antibodies against tubulin, actin myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenstrom's macroglobulinemia may express similar antibody specificities Ann Immunol (Paris) 132C 2 231 236 1:STN:280:DyaL38%2Fms1Knuw%3D%3D
59. A Servettaz, et al. 2008 Identification of target antigens of antiendothelial cell antibodies in healthy individuals: a proteomic approach Proteomics 8 5 1000 1008 10.1002/pmic.200700794 18240136 1:CAS:528: DC%2BD1cXktVeksrk%3D (Pubitemid 351441439)
60. J El Fitori, et al. 2005 Melanoma inhibitory activity (MIA) increases the invasiveness of pancreatic cancer cells Cancer Cell Int 5 1 3 10.1186/1475-2867-5-3 15710044 1:CAS:528:DC%2BD2MXjsVais7s%3D (Pubitemid 40617775)
61. J Schmidt AK Bosserhoff 2009 Processing of MIA protein during melanoma cell migration Int J Cancer 125 7 1587 1594 10.1002/ijc.24508 19521988 1:CAS:528:DC%2BD1MXpsVKmsbY%3D
62. P Hau, et al. 2004 Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma Oncol Rep 12 6 1355 1364 15547763 1:CAS:528:DC%2BD2MXitFOkuw%3D%3D
63. AK Bosserhoff R Buettner 2002 Expression, function and clinical relevance of MIA (melanoma inhibitory activity) Histol Histopathol 17 1 289 300 11813878 1:CAS:528:DC%2BD38XitVKktrg%3D
64. PP Aung, et al. 2006 Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer Oncogene 25 17 2546 2557 10.1038/sj.onc.1209279 16331256 1:CAS:528:DC%2BD28Xjs1agu7g%3D
65. J Peng, et al. 2009 A rat-to-human search for proteomic alterations reveals transgelin as a biomarker relevant to colorectal carcinogenesis and liver metastasis Electrophoresis 30 17 2976 2987 10.1002/elps.200900203 19711377 1:CAS:528:DC%2BD1MXhtVKntb%2FO
66. L Zhao, et al. 2009 Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients Mod Pathol 22 6 786 796 19329940 1:CAS:528:DC%2BD1MXntVynurg%3D
67. PD Prasad, et al. 2010 Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer Cell Tissue Res 339 2 337 347 10.1007/s00441-009-0902-y 20012321 1:CAS:528:DC%2BC3cXhslensbc%3D
68. SJ Assinder, et al. 2009 Transgelin: an actin-binding protein and tumour suppressor Int J Biochem Cell Biol 41 3 482 486 10.1016/j.biocel.2008.02.011 18378184 1:CAS:528:DC%2BD1MXns1OrtA%3D%3D
69. DR Green, et al. 2009 Immunogenic and tolerogenic cell death Nat Rev Immunol 9 5 353 363 10.1038/nri2545 19365408 1:CAS:528:DC%2BD1MXksVyit7Y%3D
70. KP Olive, et al. 2009 Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 5933 1457 1461 10.1126/science.1171362 19460966 1:CAS:528:DC%2BD1MXntVSiu7Y%3D
71. B Zhang, et al. 2007 Induced sensitization of tumor stroma leads to eradication of established cancer by T cells J Exp Med 204 1 49 55 10.1084/jem.20062056 17210731 1:CAS:528:DC%2BD2sXhtFGjsbY%3D (Pubitemid 46148755)
72. B Zhang, et al. 2008 IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers J Clin Invest 118 4 1398 1404 10.1172/JCI33522 18317595 1:CAS:528:DC%2BD1cXkt1Cnur4%3D (Pubitemid 351500433)